

Special Issue

Past, Present and Future of Protein Kinase CK2 Research

Message from the Guest Editors

Dear Colleague,

CK2 (formerly known as casein kinase 2) was the first protein kinase to be discovered in 1954. A huge number of studies have been published that tried to disclose its biochemical properties and its physiological and pathological roles. Although it has long been considered a promising pharmacological target for diverse pathologies, and several inhibitors with increasing efficacy and specificity have been developed over the years, the actual value of its targeting in cancer has been recently questioned and deserves further debate.

In this Special Issue, we will, therefore, welcome original, commentary and review contributions in all areas of CK2 research and biological systems, with emphasis on works attempting to answer outstanding questions: how can a constitutive kinase be regulated? How many substrates and molecular partners does it currently count? For which human diseases does it really represent a therapeutic target, and which are the best pharmacological strategies? We look forward to contributions on these crucial issues as well as the many others that will be identified by the numerous scientists who work on CK2 or come across this fundamental enzyme.

Guest Editors

Dr. Mauro Salvi

Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy

Prof. Dr. Maria Ruzzene

Department of Biomedical Sciences, University of Padova, Padova, Italy

Deadline for manuscript submissions

closed (30 December 2024)



Kinases and Phosphatases

an Open Access Journal
by MDPI



mdpi.com/si/172072

Kinases and Phosphatases

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

kinasesphosphatases@mdpi.com

mdpi.com/journal/

[kinasesphosphatases](https://mdpi.com/journal/kinasesphosphatases)





Kinases and Phosphatases

an Open Access Journal
by MDPI



[mdpi.com/journal/
kinasesphosphatases](https://mdpi.com/journal/kinasesphosphatases)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Dr. Mauro Salvi
Department of Biomedical Sciences, University of Padova, 35131
Padova, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 22.9 days after submission; acceptance to publication is undertaken in 1.9 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.